Medindia4m
Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA
Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the ...
MPs push for assisted dying to be expanded to people with a year left to live
MPs and campaigners say that people suffering from Motor Neurone Disease or Parkinson’s should have greater access to an ...
Alterity secures funding to advance MSA drug development
Alterity Therapeutics Limited (market cap: $40 million), a pharmaceutical company specializing in the development of therapeutic drugs, has secured A$40 million in funding to advance the development ...
Business Insider13d
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 ...
Alterity Therapeutics Raises A$40.0 million in Placement
Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders –– Capital raising was strongly supported by domestic and ...
Auburn Citizen15h
Auburn brewpub announces temporary closure
A downtown Auburn brewpub has announced that it is closing temporarily due to one of its owners having a terminal illness.
Alterity surges after mid-stage trial data for lead asset
Alterity Therapeutics (ATHE) stock jumps as its lead asset, ATH434, shows promise in slowing clinical progression in multiple ...
Morningstar12d
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase ...